IMUX
Immunic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.72
−0.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 33.0K | — | — | — | — |
| Gross Profit | (33.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 90.6M | 82.0M | 80.0M | 83.2M | 71.3M |
| SG&A Expense | 27.2M | 21.2M | 18.0M | 16.0M | 15.3M |
| General & Admin Expense | 27.2M | 21.2M | 18.0M | 16.0M | 15.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 33.0M |
| Total Operating Expenses | 117.8M | 103.2M | 98.1M | 99.2M | 119.5M |
| Cost and Expenses | 117.9M | 103.2M | 98.1M | 99.2M | 119.5M |
| Operating Income (EBIT) | (117.9M) | (103.2M) | (98.1M) | (99.2M) | (119.5M) |
| Non-Operating | |||||
| Interest Income | 2.7M | 1.0M | 3.4M | 3.1M | 1.0M |
| Interest Expense | — | — | — | — | 1.0M |
| Net Interest Income | 2.7M | 1.0M | 3.4M | 3.1M | — |
| Other Non-Op Income/Expense | 6.3M | 6.1M | (2.5M) | 5.6M | (919.0K) |
| Non-Operating Income (excl Interest) | (6.3M) | (6.1M) | 2.5M | (5.6M) | (33.0M) |
| EBT (Pre-Tax Income) | (111.6M) | (97.2M) | (100.5M) | (93.6M) | (120.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (111.6M) | (97.2M) | (100.5M) | (93.6M) | (120.4M) |
| Earnings from Cont. Ops | (111.6M) | (97.2M) | (100.5M) | (93.6M) | (120.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (111.6M) | (97.2M) | (100.5M) | (93.6M) | (120.4M) |
| Per Share | |||||
| Basic EPS | ($4.80) | ($6.24) | ($10.03) | ($21.12) | ($37.84) |
| Diluted EPS | ($4.80) | ($6.24) | ($10.03) | ($21.12) | ($37.84) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 42.5M | 15.6M | 10.0M | 4.4M | 3.2M |
| Diluted Shares Outstanding | 42.5M | 15.6M | 10.0M | 4.4M | 3.2M |
| Profitability Metrics | |||||
| EBITDA | (111.3M) | (97.0M) | (100.4M) | (93.5M) | (86.4M) |
| D&A | 216.0K | 168.0K | 134.0K | 111.0K | 77.0K |
| EBIT | (111.6M) | (97.2M) | (100.5M) | (93.6M) | (86.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026